Earlier this month, Genentech, a leading pharmaceutical company, offered numerous academics and researchers the opportunity to receive up to $125,000 in grants to produce papers that align with key talking points aimed at influencing discussions on U.S. healthcare reforms within Washington. The request for proposals emphasized the need for "rigorous, independent" work focusing on several critical areas: the potential consequences of U.S.
pricing policies on future innovation, the strategic importance of pharmaceutical discovery as a national asset, and the risks associated with research and development (R&D). According to the terms laid out in the June 30 submission deadline, Genentech aims to gather insights that can support its advocacy efforts for healthcare affordability, access, and long-term sustainability. The proposal underscores the company's belief that there is a pressing need for a deeper understanding of how biopharmaceutical innovation fits into the broader U.S.
healthcare landscape. Continue to STAT+ to read the full story…
